Receipt date 2,04/28/2008

TADEY

10589726 - GAU: 1647

ATTORNEY DOCKET NO. 22000.0129U2 APPLICATION NO. 10/589,726 SHEET 1 OF 6

INFORMATION DISCLOSURE

Complete if Known
Application Number 10/589,726
Filing Date August 17, 2006
First Named Inventor Hawiger et al.
Group Art Unit 1647

(Use as many sheets as necessary)

STATEMENT LIST

					Examiner Name		Unass	Unassigned	
		U	l.S. P/		DOCU	MENTS			702 ***
Examiner's Initials	Cite No.	Document No.				Name	Class	Subclass	Filing Date (if appropriate
-	A1	6,323,317	11/27	7/2001	Hilton et al.				
	A2	7,049,418	5/23/	2006	Hilton et al.				
	A3	6,905,842	6/14/	2005	Hiltor	n et al.	-		
	A4	3,610,795	10/5/1971		Antoi	ne, J.			
		FOR	REIGN	PATIEN	T DO	EUMENITS	ik, iller v		●配子 マーフン
Examiner's Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code		Dat	te Name I		Translation Yes/No		
	A5	WO 99/03993		1/28/19	99	Schering Corporation			
	A6	EP0045665				Szelke et al			
		IN	ON-P	ATENT	DOGU	MENTIS	The consequence of the consequence		
Examiner's Initials	Cite No.	Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication)							
	A7	Abrahmsen L et al., "Engineering subtilisin and its subtrates for efficient ligation of peptide bonds in aqueous solutions," Biochemistry, 30:4151-4159 1991							
	A8	Alexander and Douglas J. Hilton. "The role of suppressors cytokine signaling (SOCS)" 22:503–29, 2004							
	A9	Alexander et al. "Suppressors of Cytokine signaling Immune system," Nat Rev (SOCS) 2:1-7, 2002							
	A10	Alexander, W.S., "Suppressors of cytokine signalling (SOCS) in the immune system" Nat Rev Immunol 2, 410-6, 2002							
	A11	Almquist et al., "Synthe (1980)		d biologic	al activ	ity of a ketomethy	lene," J. M	ed. Chem 2	3:1392-1398
	A12	Arad, G., Levy, R., Hillman, D. & Kaempfer, R. "Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation." Nat Med 6, 414-21 (2000).							
	A13	Baggiolini M et al. "Interleukin-8, a chemotactic and inflammatory cytokine," FEBS Lett. 307:97-101, 1992							
	A14	Bagshawe, et al., "A cytotoxic agent can be generated selectively at cancer sites." Br. J. Cancer, 58:700-703, (1988)							
	A15	Bagshawe, K.D., "The First Bagshawe lecture. Towards generating cytotoxic agents at cancer sites." Br. J. Cancer, 60:275-281, (1989)							
	A16	Balaban, N. & Rasooly, A. "Analytical chromatography for recovery of small amounts of staphylococcal enterotoxins from food." Int J Food Microbiol 64, 33-40 (2001).							
<u> </u>	A17	Battelli, et al., "T lymphocyte killing by a xanthine-oxidase-containing immunotoxin." Cancer Immunol. Immunother., 35:421-425, (1992)							
	A18	Benner, "Expanding the genetic lexicon: incorporating non-standard amino acids into proteins be ribosome-based synthesis." TIB Tech, 12:158-163 (1994)					proteins by		
	A19		"The role of SOCS-3 in leptin signaling and le			ptin resista	nce." J. Biol	. Chem.274,	

Examiner Signature:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ATTORNEY DOCKET NO. 22000.0129U2 APPLICATION NO. 10/589,726 SHEET 2 OF 6

		Com	plete if Known	
INFORM	MATION DISCLOSURE	Application Number	10/589,726	
	TATEMENT LIST	Filing Date	August 17, 2006	
		First Named Inventor	Hawiger et al.	
(Use a	s many sheets as necessary)	Group Art Unit	1647	
		Examiner Name	Unassigned	
A20	Brown and Greene, "Molecular and cell	ular mechanisms of recept	or-mediated endocytosis." DNA	
	and Cell Biology 10:6, 399-409 (1991)			
A21	Cahill et al., "Site-specific mutagenesis	s with unnatural amino acids." TIBS, 14(10):400-403 (1989)		
A22	Car, B.D. et al. "Interferon gamma rece Med 179, 1437-44 (1994).	ptor deficient mice are resistant to endotoxic shock." J Exp		
A23	Cavaillon, J.M., Adib-Conquy, M., Fitting Scand J Infect Dis 35, 535-44 (2003).	g, C., Adrie, C. & Payen, D. "Cytokine cascade in sepsis."		
A24	Clark Lewis I et al., "Chemical synthesis, purification, and characterization of two inflammatory proteins, Neutrophil activating peptide 1 (interleukin-8) and neutrophil activating peptid 2." Biochemistry, 30:3128 (1991)			
A25	Clark Lewis I et al., "Structural requirem analogs and CXC chemokine hybrids."	ments for interleukin-8 function identified by design of " J.Biol.Chem., 269:16075-16081 (1994)		
A26				
A27	Croker, B.A. et al. "SOCS3 negatively regulates IL-6 signaling in vivo." Nat Immunol 4, 540-5 (2003).			
A28	Dawson et al. Synthesis of Proteins by Native Chemical Ligation. Science, 266:776 779, 1994			
A29	De Lisle Milton, R.C. et al., "Synthesis of Proteins by Chemical Ligation of Unprotected Peptide Segments: Mirror-Image Enxyme Molecules, D- & L-HIV Protease Analogs" Techniques in Protein Chemistry IV. Academic Press, New York, pp. 257 267 (1992)			
A30	Dinges, M.M., Orwin, P.M. & Schlievert, P.M. "Exotoxins of Staphylococcus aureus." Clin Microbiol Rev 13, 16-34, (2000).			
A31	Drakas R et al. "A modified tandem affir complexes in mammalian cells." Proteo		ue for the purification of protein	
A32	Emanuelli, B. et al, "SOCS-3 Is an insul Chem. 275, 15985-15991 (2000)		tor of insulin signaling." J.Biol.	
A33	Fey, P.D. et al. "Comparative molecular resistant Staphylococcus aureus." Antin			
A34	Fitzgerald, K.A. et al. "LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF." J Exp Med 198, 1043-55 (2003).			
A35	Hann M. et al. "On the double bond isostere of the peptide bond: preparation of an enkephalin analogue." Chem. Soc Perkin, 307-314 (1982)			
A36	Hawiger, J. "Cellular import of functional peptides to block intracellular signaling." Curr Opin Immunol 9, 189-94 (1997).			
A37	Hawiger, J. "Innate immunity and inflam 109 (2001).	·		
A38	Hawiger, J. "Noninvasive intracellular de Chem Biol 3, 89-94 (1999).	elivery of functional peptide	es and proteins." Curr Opin	
A39	Hoebe, K. et al. "Identification of Lps2 a Nature 424, 743-8 (2003).	as a key transducer of MyD	88-independent TIR signaling."	

Examiner Signature:	Date Considered:			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if				
not in conformance and not considered. Include conv of this form with next communication to applicant				

ATTORNEY DOCKET NO. 22000.0129U2 APPLICATION NO. 10/589,726 SHEET 3 OF 6

		Complete if Known		
INFORM	MATION DISCLOSURE	Application Number	10/589,726	
S	TATEMENT LIST	Filing Date	August 17, 2006	
		First Named Inventor	Hawiger et al.	
(Use a	as many sheets as necessary)	Group Art Unit	1647	
		Examiner Name	Unassigned	
A40	Holladay et al. "Synthesis of hydroxye	thlyene and ketomethylene	dipeptide isosteres,	
	Tetrahedron." Lett 24:4401-4404 (198			
A41	Hotamisligil, G. S., "Inflammatory path 55,(2003)			
A42	Hruby, "Conformational restrictions of Life Sci 31:189-199 (1982)			
A43	Hudson, D. et al., "Methionine enkeph support." Int J Pept Prot Res 14:177-1		. I. Synthesis on a phenolic res	
A44	Hughes et al.," Monoclonal antibody to Research, 49:6214-6220, (1989)	argeting of lipsomes to mous	se lung in vivo." Cancer	
A45	Ibba and Hennecke, "Towards engine natural amino acids." Bio/technology,		ed incorporated in vivo of non-	
A46	Ibba,M., "Strategies for in vitro and in Biotechnology & Genetic Engineering	vivo translation with non-nat		
A47		Inthetic oligonucleotides." Rev. Biochem. 53:323-356 (1984)		
A48	Inagaki-Ohara K, Hanada T, Yoshimura A., "Negative regulation of cytokine signaling and inflammatory diseases." Curr Opin Pharmacol. 3:435-42 2003. Ivashkiv LB, Tassiulas I., "Can SOCS make arthritis better?" J Clin Invest.; 111, 795-7 2003			
A49				
A50	Jaeger et al., "Predicting optimal and 183:281-306, 1989	suboptimal secondary struct	ure for RNA." Methods Enzymo	
A51	Jaeger et al., "Improved predictions of 86:7706-7710, 1989	f secondary structures for RI	NA." Proc. Natl. Acad. Sci. US.	
A52	Jennings-White et al., "Synthesis of k 23:2533-2534 (1982)	ketomethylene analogs of dip	peptides." Tetrahedron Lett	
A53	Jo et al., "Intracellular Protein Therapy Med., 11, 892-898 2005	y with SOCS3 Inhibits Inflam	mation and Apoptosis." Nature	
A54	Jo, D. et al., "Cell cycle-dependent tra Cell Biochem 89, 674-87 (2003).	ansduction of cell-penetrating	Cre recombinase proteins." J	
A55	Jo, D. et al., "Epigenetic regulation of gene structure and function with a cell-permeable Cre recombinase." Nat Biotechnol 19, 929-33 (2001).		with a cell-permeable Cre	
A56	Krebs, D.L. & Hilton, D.J. "SOCS proteins: negative regulators of cytokine signaling." Stem Cell 19, 378-87 (2001).			
A57	Krebs, D.L. & Hilton, D.J. "SOCS: physiological suppressors of cytokine signaling." J Cell Sci 11: 2813-9 (2000).			
A58	Kunkel et al. "Rapid and efficient site- Enzymol. 1987:154:367, 1987	specific mutagenesis withou	t phenotypic selection." Method	
A59	Lang, R. et al., "SOCS3 regulates the	plasticity of gp130 signaling	." Nat Immunol 4, 546-50 (2003	
A60	Larsen et al., "Suppressors of Cytokir 12, pages 833-844	ne Signaling: SOCS." APMIS	December 2002, Vol 110. No.	
A61	Lee, J.Y. & Sullivan, K.E., "Gamma in transcription to induce tumor necrosis			
	re:	Date Considered:	, , , , , , , , , , , , , , , , , , , ,	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ATTORNEY DOCKET NO. 22000.0129U2 APPLICATION NO. 10/589,726 SHEET 4 OF 6

		Com	plete if Known	
INFORM	ATION DISCLOSURE	Application Number	10/589,726	
1	ATEMENT LIST	Filing Date	August 17, 2006	
	/	First Named Inventor	Hawiger et al.	
(Use as	s many sheets as necessary)	Group Art Unit	1647	
		Examiner Name	Unassigned	
A62	Letsinger et al., "Cholesteryl-conjugate	<u> </u>		
AOZ	inhibitors of replication of human immur			
	86, 6553 6556, 1989	loadholdhoy vii ao odii oalta	10. 1 100. Nati. / toda: 00i. 00/1,	
A63	Litzinger and Huang, Biochimica et Biop	physica Acta, 1104:179-18	7, (1992)	
A64	Liu, D. et al. "Suppression of Staphyloco			
	Inhibitor." J Biol Chem 279, 19239-46 (2			
A65	Madsen, J.M. "Toxins as weapons of m	ass destruction. A compari	son and contrast with biological-	
	warfare and chemical-warfare agents."	Clin Lab Med 21, 593-605	(2001).	
A66	Mattix, M.E., Hunt, R.E., Wilhelmsen, C			
	staphylococcal enterotoxin B-induced p	ulmonary lesions in rhesus	monkeys (Macaca mulatta)."	
	Toxicol Pathol 23, 262-8 (1995).			
A67	Miethke, T. et al. "T cell-mediated lethal			
400	staphylococcal enterotoxin B: critical rol			
A68	l • • ·	gulatory peptides by structural modification." Trends Pharm		
A69	Sci pp. 463-468,1980	ovovvoliaonuolootidos hy t	ha madified trimester method "	
A09	Methods Enzymol., 65:610-620 (1980)	exoxyoligonucleotides by the modified trimester method."		
A70		ethod applicable to the sea	rch for similarities in the amino	
	Needleman and Wunsch, "A general method applicable to the search for similarities in the amino acid sequence of two proteins." J. MoL Biol. 48: 443-453 (1970)			
A71	Nielsen et al., "Petide nucleic acid (PNA		otide backbone." Bioconjug.	
	Chem. 5:3-7 (1994)			
A72	NIH Grant No. HL68744. "Functional G	enomics of Inflammation"	1/26/01	
A73	NIH Grant No. HL69542. "Superantigen	-Induced Vascular Injury a	nd DIC" 3/27/01	
A74	O'Keefe, G.M., Nguyen, V.T., Ping Tang	g, L.L. & Benveniste, E.N.	'IFN-gamma regulation of class	
	II transactivator promoter IV in macroph		ement of the suppressors of	
	cytokine signaling-1 protein." J Immuno	l 166, 2260-9 (2001).		
A75		pter molecule (TICAM)-2, a bridging adapter recruiting to toll-		
	like receptor 4 TICAM-1 that induces in			
A76		for biological sequence comparison." Proc. Natl. Acad. Sci.		
A 77	U.S.A. 85: 2444 - 2448 (1988)	FE led turner persons foots	recenter ore recistors to	
A77		e 55 kd tumor necrosis factor receptor are resistant to		
A78		onocytogenes infection." Cell 73, 457-67 (1993). ijugates for the treatment of cancer." Immunolog. Reviews,		
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	129:57-80, (1992)	agates for the treatment of	cancer. minutolog. Reviews,	
A79	Poltorak, A. et al. "Defective LPS signal	ling in C3H/HeJ and C57Bl	/10ScCr mice: mutations in Tlr4	
	gene." Science 282, 2085-8 (1998).	3		
A80	Prescilla et al. http://www.emedicine.co	m, Immunology of Transpla	ant Rejection, updated June 20,	
	2003)			
A81	Rajagopalan, G., Smart, M.K., Krco, C.,			
	HLA-DQ molecules and lymphocyte de-	velopment in mice lacking i	nvariant chain." J Immunol 169,	
	1774-83 (2002).			

Examiner Signature:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ATTORNEY DOCKET NO. 22000.0129U2 APPLICATION NO. 10/589,726 SHEET 5 OF 6

		Com	plete if Known	
INFORM	NATION DISCLOSURE	Application Number	10/589,726	
	TATION DISCLOSURE	Filing Date	August 17, 2006	
]	ATEMENT LIST	First Named Inventor	Hawiger et al.	
(Use a	s many sheets as necessary)	Group Art Unit	1647	
(000 t	o many oneste as necessary,	Examiner Name		
		<u> </u>	Unassigned	
A82	Rizo and Gierasch, "Constrained peptid		ptides and protein	
	substructures." Ann. Rev. Biochem. 61:			
A83		nide prodrug treatment of human tumor cells targeted with a		
		em. Pharmacol, 42:2062-2065, (1991)		
A84	Rottapel R., "Putting the brakes on arth		tokine signaling (SOCS)	
	suppress rheumatoid arthritis?" J Clin Ir		100000011	
A85	Rui, L., Yuan, M., Frantz, D., Shoelson,			
100	signaling by ubiquitin-mediated degrada			
A86	Sambrook et al., Molecular Cloning: A L			
	Laboratory Press, Cold Spring Harbor, I	N.Y., 1989) Chapter 5 "Enz	zymes used in Molecular	
A07	Cloning"	abaratani Manual Ond Ed	Han (Cold Caring Harbor	
A87	Sambrook et al., Molecular Cloning: A L			
100	Laboratory Press, Cold Spring Harbor,			
A88		eins by dovetailing unprotected synthetic peptides:		
A89	Backbone-engineered HIV protease." S		y managland antibody autosina	
A09	deaminase conjugates." Bioconjugate	racil from 5-fluorocytosine by monoclonal antibody-cytosine		
A90	Senter, et al., "Generation of cytotoxic a		s " Rioconiugate Chem 4:3-9	
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	(1993)	agents by targeted enzyme	3. Bioconjugate Onem., 4.0 0,	
A91	Shouda, T. et al., "Induction of the cytol	kine signal regulator SOCS	3/CIS3 as a therapeutic strategy	
	for treating inflammatory arthritis." J Clin			
A92	Smith and Waterman, Comparison of b			
A93	Spatola et al., "Structure-activity relation			
	thimethylene amide bond surrogates." L			
A94	Spatola, A. F., Vega Data (March 1983)			
	Structure-Activity Analysis of Peptides	Containing Amide Bond Surrogates. (general review), Chap		
	5., pages 267 - 357			
A95	Starr R, Hilton DJ SOCS: suppressors	of cytokine signaling. Int J I	Biochem Cell Biol.30(10):1081-5	
	(1998 Oct)			
A96	Starr, R. et al. "A family of cytokine-indu	ducible inhibitors of signaling." Nature 387, 917-21 (1997).		
A97	Stoiber, D. et al. "Lipopolysaccharide in	duces in macrophages the	synthesis of the suppressor of	
	cytokine signaling 3 and suppresses sig	gnal transduction in respon	se to the activating factor IFN-	
	gamma." J Immunol 163, 2640-7 (1999)			
A98	Suzuki, A. et al. "CIS3/SOCS3/SSI3 pla	ays a negative regulatory ro	ble in STAT3 activation and	
	intestinal inflammation." J Exp Med 193			
A99	Thorson et al., "A Biosynthetic Approac		Innatural Amino Acids Into	
	Proteins" Methods in Molecular Biology			
A100	Uysal, K.T. et al, "Protection from obesi	ity-induced insulin resistand	ce in mice lacking TNF function."	
	Nature 389:610-614 1997			
A101	Veach, R.A. et al. "Receptor/transporter	,	functional peptides across the	
	plasma membrane." J Biol Chem 279, 1	11425-31 (2004).		

Examiner Signature:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Receipt date: 04/28/2008

10589726 - GAU: 1647

ATTORNEY DOCKET NO. 22000.0129U2 APPLICATION NO. 10/589,726 SHEET 6 OF 6

INFORM	MATION DISCLOSURE	Application Number	10/589,726
S [·]	TATEMENT LIST	Filing Date	August 17, 2006
2 = =		First Named Inventor	Hawiger et al.
(Use a	as many sheets as necessary)	Group Art Unit	1647
		Examiner Name	Unassigned
A102	Yasuda, S., Nagaki, M. & Moriwaki, H. lethal shock in endotoxin-resistant C3l Endotoxin Res 8, 253-61 (2002).		
A103	Yasukawa, H. et al. "IL-6 induces an a macrophages." Nat Immunol 4, 551-6		the absence of SOCS3 in
A104	Yasukawa, H., Sasaki, A. & Yoshimura Annu Rev Immunol 18, 143-64 (2000).	a, A. "Negative regulation of	cytokine signaling pathways.
A105	Yeung, R.S. et al. "Human CD4 and he transgenic mice: supersensitivity to su 82 (1996).	uman major histocompatibili	
A106	Zhang, J.G. et al. "The SOCS box of s of cytokine action in vivo." Proc Natl A		
A107	Zoller, "New recombinant DNA methodology for protein engineering." Current Opinion in Biotechnology, 3:348-354 (1992)		
A108	Zuker, "On finding all suboptimal foldi	ngs of an RNA molecule." M	I. Science 244:48-52, 1989
		-	

Examiner Signature: /Bridget E. Bunner/	Date Considered: 12/23/2009				
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if					
not in conformance and not considered. Include copy of this form with next communication to applicant.					